Mizolastine

證據等級: L5

預測適應症: 10 個

Mizolastine: From Allergic Conditions to Acute Intermittent Porphyria

One-Sentence Summary

Mizolastine is a second-generation selective H₁ receptor antagonist, commercially available as an antiallergy medication in multiple countries outside the US (marketed as Mizollen®). The TxGNN model predicts it may be effective for Acute Intermittent Porphyria with a prediction score of 99.76%, however no clinical trials and no supporting publications have been identified for this indication, placing this prediction at the lowest evidence tier.

Quick Overview

Item	Content
Original Indication	Allergic conditions (antiallergy / antihistamine)
Predicted New Indication	Acute Intermittent Porphyria
TxGNN Prediction Score	99.76%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Mizolastine (MKC-431 / SL-850324) is a selective H₁ receptor antagonist targeting the histamine H₁ receptor encoded by the HRH1 gene (Entrez: 3269, ENSEMBL: ENSG00000196639). Unlike first-generation antihistamines, Mizolastine is a second-generation agent with low central nervous system penetration, meaning its primary pharmacological activity is peripheral H₁ blockade. It is available internationally (e.g., Mizollen®) but has not received US FDA approval.

Acute Intermittent Porphyria (AIP) is a metabolic disorder caused by a deficiency in hydroxymethylbilane synthase (porphobilinogen deaminase), leading to accumulation of δ-aminolevulinic acid (ALA) and porphobilinogen. The theoretical mechanistic link to Mizolastine is extremely tenuous: histamine has been proposed to indirectly modulate neurological regulation of ALA synthase activity, and H₁ receptor blockade might theoretically influence this pathway. However, this connection has no published experimental or clinical basis.

Critically, there is an important safety concern that actually works against this repurposing hypothesis: several antihistamine-class drugs have been reported to trigger or exacerbate acute porphyria attacks. This means the risk-benefit ratio for this specific indication may be unfavorable without considerably more mechanistic evidence. The TxGNN prediction likely arises from network topology proximity in the knowledge graph rather than a pharmacologically sound mechanistic rationale.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Mizolastine is currently not marketed in India. No drug licenses or regulatory approvals are on record.

Safety Considerations

Pharmacological Target: Mizolastine acts as a selective antagonist at the human H₁ receptor (HRH1 gene). Its clinical use is as an antiallergy agent; it is not approved in the US.
Key Safety Concern for This Indication: Multiple antihistamine agents are classified as potentially porphyrinogenic — i.e., capable of precipitating acute attacks in patients with AIP. This is a critical contraindication consideration that must be investigated before any repurposing evaluation proceeds.

For full prescribing warnings, contraindications, and drug interaction data, please refer to the approved package insert (e.g., Mizollen® SmPC).

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is currently supported only by TxGNN model output (L5 evidence) with zero clinical trials, zero literature, and a mechanistic link that is speculative at best and potentially hazardous — antihistamines as a class carry a known risk of inducing acute porphyria attacks, making Mizolastine a particularly questionable candidate for AIP repurposing without substantially more investigation.

To proceed, the following is needed:

Safety clearance: Conduct a formal porphyrinogenicity assessment for Mizolastine specifically (in vitro ALA induction assay; review of case reports for antihistamine-triggered AIP attacks)
Mechanistic validation: Obtain and review the complete MOA profile from DrugBank (DG002 data gap), including any known off-target activities beyond H₁ antagonism
Regulatory package insert review: Retrieve TFDA or EMA/MHRA package inserts for full contraindications and warnings (DG001 data gap)
India regulatory pathway: As Mizolastine is not marketed in India, a full regulatory strategy (new drug application) would be required before any clinical development
Expert consultation: Engage a metabolism/rare disease specialist to evaluate whether any H₁-independent mechanisms (e.g., mast cell stabilisation, anti-inflammatory effects) could plausibly address AIP pathophysiology
If safety data clears, consider a preclinical AIP animal model study before any human investigation

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any clinical application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.